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1. Introduction  
The ordered electrical excitation of the heart via the cardiac conduction system coordinates 
the efficient pumping of blood. Electrical impulses normally originate in the sinoatrial node 
and then propagate through the atria, atrioventricular node, and into the ventricles. The 
electrical activity of the heart can be measured non-invasively using an electrocardiogram 
(ECG). An ECG reflects the summed electrical activity of the individual contractile myocytes 
in the different regions of the heart over time. The first event is the “P wave” and 
corresponds to the depolarization of the atria, the next three waves “Q, R, and S” represent 
the progressive wave of depolarization through the ventricles, and the final wave of the 
cardiac cycle “T” corresponds to ventricular repolarization. The action potentials of 
contractile atrial and ventricular myoctes share several common characteristics: a stable 
resting or diastolic membrane potential (phase 4), a rapid depolarization (phase 0), an initial 
repolarization (phase 1), a plateau (phase 2), and a rapid repolarization to diastolic potential 
(phase 3). The different phases of the cardiac action potential reflect changes of the 
sarcolemma permeability to K+, Na+, and Ca2+. Figure 1 shows the relationship between the 
ECG, a ventricular action potential, and several of the important ventricular K+, Na+, and 
Ca2+ currents (Nerbonne and Kass, 2005). 
Arrhythmias are electrical disturbances that disrupt the normal initiation or propagation of 
the cardiac impulse. They cause abnormal impulse rates (bradycardia or tachycardia), block 
impulse propagation, or initiate the impulse to circle in a “reentry” loop. Atrial arrhythmias 
can result in the formation of blood clots and increase the risk of stroke, whereas ventricular 
arrhythmias can cause the inefficient pumping of blood, loss of consciousness, and 
sometimes death (Shah et al., 2006).  
“Cardiac channelopathies” are caused by mutations in ion channel genes that encode the 
proteins that underlie the K+, Na+, or Ca2+ currents that shape the cardiac action potential 
(Figure 1). These mutations can cause syndromes that increase the risk for atrial and/or 
ventricular arrhythmias. Cardiac channelopathies typically cause a “gain- or loss-of-
function” in one of these currents by altering channel synthesis, channel transport to and 
from the cell surface membrane (trafficking), channel gating, and/or single channel 
permeation (Figure 2) (Delisle et al., 2004). This chapter provides a description for several 
different cardiac syndromes that can be caused by channelopathies and the utilization of the 
patch-clamp technique to learn about functional phenotypes. 
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Fig. 1. The relationship between an ECG trace, a ventricular action potential, and important 
K+, Na+, and Ca2+ currents. The P, Q, R, S, T correspond to the different waves on the ECG, 
the 4, 0, 1, 2, 3 correspond to the different phases of the ventricular action potential. IK1 is the 
inwardly rectifying K+ current, INa represents the Na+ current, ICa represents the Ca2+ 
current, IKs is the slowly activating delayed rectifier K+ current, and IKr is the rapidly 
activating delayed rectifier K+ current. 
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Fig. 2. A cartoon showing the synthesis, trafficking, and surface expression of ion channels. 
Macroscopic current (I) is a function of channel number at the cell surface (n), open 
probability (Po), and the amplitude of the single channel current (i). Cardiac channelopathy 
mutations can alter n by changing synthesis and trafficking, or they can alter channel 
function by changing gating and selectivity (hRNA = heterogeneous ribonucleic acid; 
mRNA = messenger ribonucleic acid; ER = Endoplasmic Reticulum; ERGIC = ER Golgi 
Intermediate Compartment). 
2. Cardiac channelopathies 
Hundreds of different mutations in over a dozen different genes that encode cardiac K+, Na+ 
and Ca2+ channels or their regulatory proteins are linked to several different congenital 
arrhythmia syndromes including Long QT syndrome, Short QT syndrome, Brugada 
Syndrome, and familial Atrial Fibrillation (Lehnart et al., 2007).  
2.1 Long QT syndrome 
Congenital Long QT syndrome (LQT) is typically characterized by an abnormally long 
corrected QT (QTc) interval on an ECG. It is one of the most common “monogenic” 
arrhythmia syndromes and occurs in ~1:2,500 healthy births (Lehnart et al., 2007; Crotti et 
al., 2008). LQT-linked mutations are postulated to cause a prolongation of the plateau phase 
of the ventricular action potential. This allows L-type Ca2+ channels to recover from 
inactivation and reopen, which leads to an early after depolarization. Early after 
depolarizations increase risk for polymorphic ventricular tachycardia (torsade de pointes), 
which can cause a loss of cardiac output, syncope, and sudden death. The majority of LQT-
linked mutations follow a dominant inheritance pattern (Romano-Ward type of LQT), and it 
is linked to at least thirteen different genes (LQT1-LQT13; Table 1) (Delisle et al., 2004; Ruan 
et al., 2008); however, autosomal-recessive forms, Jervell and Lange-Nielsen syndrome  
(JLN) exist and are caused by homozygous or compound mutations in KCNQ1 and KCNE1. 
Most LQT-linked mutations cause a prolongation of the ventricular action potential 
www.intechopen.com
 Patch Clamp Technique 
 
236 
duration by either decreasing cardiac K+ currents, or increasing the “late” Na+ or Ca2+ 
current. LQT1-3 account for 70-75% of all LQT cases, and the other 9 forms contribute an 
additional 5% (Kapa et al., 2009). The types of LQT mutations include splice, nonsense, 
frameshift, deletions, and missense, the latter type represents ~70% of the case-linked 
mutations.  
 
Disease Current               Chromosome Defective gene (protein) Frequency Key reference 
LQT1 IKs,  amplitude 11p15.5 KCNQ1 (Kv7.1) ~30-35% Wang, et al., 1996 
LQT2 IKr,  amplitude 7q35-q36 KCNH2, hERG (Kv11.1) ~30-35% Curran et al., 1995 
LQT3 INa, late 
amplitude 
3p22.2 SCN5a (Nav1.5) ~7-10% Wang et al., 1995 
LQT4 cell Ca2+ 4q25-4q26 ANKB Rare  Schott et al., 1995, 
     Mohler et al., 2003 
LQT5 IKs, amplitude 21q22.1-22.2 KCNE1 (MiNK1) Rare  Splawski et al., 1997 
LQT6 IKr,  amplitude 21q22.11 KCNE2 (MiRP1) Rare  Abbott et al., 1999 
LQT7 IK1,  amplitude 17q23-
17q24.2 
KCNJ2 (Kir2.1) Rare Tristani-Firouzi et al., 
2002; Andelfinger et 
al., 2002. 
LQT8 ICa,  amplitude  12p13.33 CACNA1C (Cav1.2) Rare Splawski et al., 2005 
LQT9 INa,  late current 3p25 CAV3 (caveolin 3) Rare Vatta et al., 2006 
LQT10 INa,  late current 11q23 SCN4B Rare Medeiros-Domingo et 
al., 2007 
LQT11 IKs,  amplitude 7q21-q22 AKAP9 (Yotiao) Rare Chen et al., 2007 
LQT12 INa,  late 
amplitude 
20q11.2 SNTA1 (syntrophin-ǂ1) Rare Ueda et al., 2008 
LQT13 IKATP,  amplitude 11q24.3 KCNJ5 (Kir3.4) Rare  Yang et al., 2010 
JLN1 IKs,  amplitude 11p15.5 KCNQ1 (Kv7.1) Rare  Neyroud et al., 1997 
JLN2 IKs,  amplitude 21q22.1-22.2 KCNE1 (MiNK1) Rare  Schultze-Bahr et al., 
1997 
Table 1. Long QT syndrome disease types. Autosomal dominant forms (LQT1-12) include 
Romano Ward Syndrome (LQT1-6), Anderson Tawill Syndrome (LQT7), and Timothy 
Syndrome (LQT8). The autosomal recessive form is Jervell Lange-Neilson syndrome (JLN1-
2) and is associated with deafness. 
2.2 Short QT syndrome 
Short QT syndrome (SQT) is characterized by a short QTc interval and can cause syncope, 
paroxysmal atrial fibrillation, and ventricular fibrillation (Lehnart et al., 2007; Patel et al.,  
 
Disease Current Chromosome Defective gene (protein) Key reference 
SQT1 IKr,  amplitude 7q35-q36  KCNH2, hERG (Kv11.1)  Brugada et al., 2004 
SQT2 IKs,  amplitude 11p15.5 KCNQ1 (Kv7.1) Bellocq et al., 2004 
    Hong et al., 2005 
SQT3 IK1,  amplitude 17q23-17q24.2 KCNJ2 (Kir2.1) Priori et al., 2005 
SQT4 ICa,  amplitude 12p13.33 CACNA1C (Cav1.2) Antzelevitch et al., 
2007 
SQT5 ICa,  amplitude 10p12.33-p12.31 CACNB2 (Cavǃ2) Antzelevitch et al., 
2007 
Table 2. Short QT syndrome disease types. 
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2010). Similar to LQT, SQT follows a dominant inheritance pattern, but it is extremely rare 
and only a small number of families with missense mutations have been identified. SQT 
mutations are predicted to shorten the ventricular action potential duration by increasing 
cardiac K+ currents or decreasing Ca2+ current. 
2.3 Brugada syndrome 
Brugada syndrome (BrS) is characterized by ST segment elevation, conduction abnormalities 
(prolonged PR or QRS segments), and an increased risk of ventricular fibrillation (Lehnart et 
al., 2007). The prevalence of Brugada syndrome is slightly more common than LQT at 
~1:2,000. The ECG changes are not always obvious but they can be usually seen after the 
administration of drugs that block the cardiac Na+ current. The majority of BrS patients have 
missense, nonsense, deletion, or insertion mutations in SCN5A that cause a reduction in Na+ 
current (Table 3). There appears to be much more genetic heterogeneity associates with 
Brugada syndrome, because ~2/3rds of the patients do not have a clear genotyped link. BrS-
related cardiac events occur more often in adult men (this is likely because of gender 
differences in cardiac ion channel expression and hormone levels).  
 
Disease Current Chromosome Defective gene 
(protein) 
Frequency Key reference 
BrS1 INa,  amplitude 3p22.2 ScN5a (Nav1.5) ~10-30% Chen, et al., 1998 
BrS2 INa,  amplitude 3p22.3 GPDL1 (GPDL1) Rare London et al., 2007 
     Van Norstrand et 
al., 2007 
BrS3 ICa,  amplitude 12p13.33 CACNA1C 
(Cav1.2) 
Rare Antzelevitch et al., 
2007 
BrS4 ICa,  amplitude 10p12.33-p12.31 CACNB2 (Cavǃ2) Rare  Antzelevitch et al., 
2007 
BrS5 INa,  amplitude 19q13.12 SCN1B (Navǃ1) Rare  Watanabe et al., 
2008 
BrS6 ITO,  amplitude 11q13.4 KCNE3 (MiRP2) Rare  Delpon et al., 2008 
BrS7 INa,  amplitude 11q24.1 SCN3B (Navǃ3) Rare Hu et al., 2009 
BrS8 IF,  amplitude  15q24.1 HCN4 (HCN4) Rare Ueda et al., 2009 
BrS9 ICa,  amplitude 7q21.11 CACNA2D1 (ǂ2ζ) Rare Burashnikov et al., 
2010 
Table 3. Brugada syndrome disease types.  
2.4 Familial Atrial Fibrillation 
The most common arrhythmia is Atrial Fibrillation (AF), and it is usually secondary to 
structural changes in the heart (i.e. organ heart disease, valvular disease, hypertensive heart 
disease, cardiac hypertrophy, etc.). In some instances AF in the absence of structural heat 
disease (lone AF) occurs, and it is typically caused by genetic factors. Mutations in ion 
channel genes linked to familial forms of AF have been identified, but these mutations in 
these genes only account for a small number of cases (Lehnart et al., 2007). 
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Disease Current Chromosome Defective gene 
(protein) 
Key reference 
ATFB3 IKs, amplitude 11p15.5 KCNQ1 (Kv7.1) Chen et al., 2003 
ATFB4 IKs, amplitude 21q22.11 KCNE2 (MiRP1) Yang et al., 2004 
ATFB7 IKur,  amplitude 12p13.32 KCNA5 (Kv1.5) Olson et al., 2006 
    Yang et al., 2009 
ATFB9 IK1, amplitude 17q24.3 KCNJ2 (Kir2.1) Xia et al., 2005 
ATFB10 INa,  or 
amplitude 
3p22.2 SCN5a (Nav1.5) Darbar et al., 2008 
    Ellinor et al., 2008 
    Makiyama et al., 2008 
    Benito et al., 2008 
ATFB11 ICNX40,  amplitude 1q21.2 GJA5 (connexin 40) Gollob et al., 2006 
ATFB12 IKATP,  ADP 
current 
12p12.1 ABCC9 (Sur2A) Olson et al., 2007 
Table 4. Familial Atrial Fibrillation syndrome disease types linked to channelopathies. 
2.5 Summary  
Many different types of cardiac arrhythmias are linked to channelopathies. Thus far, 
mutations in over 20 different genes that encode cardiac ion channel ǂ-subunits, auxiliary 
channel subunits, or channel modulatory proteins are linked to one or more arrhythmia 
syndromes. This genetic heterogeneity has identified ion channel and macromolecular 
signaling complexes that are important for normal cardiac excitability and arrhythmia 
susceptibility. Many of these mutations are predicted to increase or decrease the 
macroscopic K+, Na+ or Ca2+ currents to increase arrhythmia susceptibility. This occurs by a 
number of different mechanisms, including alterations in protein synthesis, trafficking 
to/from the membrane, channel gating, and/or permeation. 
3. Patch clamp techniques to study disease mechanisms 
This section focuses on using the patch clamp technique to study disease mechanisms linked 
to the genetic variants in KCNQ1 or KCNH2, which encode the voltage-gated K+ channel ǂ-
subunits that underlie IKs (Kv7.1) and IKr (Kv11.1), respectively. Each Kv ǂ-subunit has six 
transmembrane (TM) segments that form a voltage-sensor (TM1-TM4) and a pore domain 
(TM5-TM6) (Figure 3).  
Mutations in these genes are the most common cause of “monogenic” arrhythmia 
syndromes (Lehnart et al., 2007; Kapa et al., 2009). KCNQ1 and KCHN2 mutations can cause 
a loss- or gain-of-function (Wang et al., 1996; Neyroud et al., 1997; Chen et al., 2003). Loss of 
function mutations can be splice-site, nonsense, or frame-shift and result in 
haploinsufficiency; however, the vast majority of KCNQ1 and KCNH2 mutations linked to 
arrhythmia syndromes are missense. In syndromes that follow a dominant inheritance 
pattern (i.e. LQT, SQT, familial atrial fibrillation, etc) these mutant ǂ-subunits may co-
assemble with wild type to generate functional phenotypes that cause a more severe 
phenotype  (Figure 4).  
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Fig. 3. A cartoon of a single Kv7.1 ǂ-subunit and its putative auxiliary subunit KCNE1. The 
image shows  a single Kv7.1 ǂ-subunit and a single KCNE1 subunit. The membrane is 
represented by the purple rectangles, the individual amino acids are shown as small circles, 
and the secondary structures (ǂ-helices) are shown as cylinders. The respective amino and 
carboxy termini are labeled NH3+ and COO-, respectively. Heterolgous expression studies 
suggest that co-expression of Kv7.1 and KCNE1 are needed to generate macroscopic 
currents similar to native IKs in the heart (Barhanin et al., 1996; Sanguinetti et al., 1996). 
3.1 Long QT type 1 
Thus far, hundreds of different mutations in KCNQ1 have been linked to LQT1. Kv7.1 
tetramerizes to form the aqueous channel of the IKs in the heart (Kapa et al., 2009; 
http://www.fsm.it/cardmoc/). Mutations in KCNQ1 account for ~30-35% of congenital 
LQT cases (Yuan et al., 2008; Kapa et al., 2009). Heterologous expression studies suggest that 
many LQT1 mutations throughout Kv7.1 cause a loss-of-function (Wollnik et al., 1997; 
Neyoud et al., 1998; Saarinen et al., 1998; Yamashita et al., 2001; Pippo et al., 2001; Deschênes 
et al., 2003; Yamaguchi et al., 2003; Thomas et al., 2005; Thomas et al., 2010). 
LQT1 patients exhibit a wide-range of clinical phenotypes from asymptomatic to recurrent 
episodes of syncope and sudden cardiac arrest, and LQT1-related cardiac events are most 
often triggered by exercise (Priori et al., 2003; Napolitano et al., 2005; Schwartz et al., 2001; 
Priori et al., 2004; Ruan et al., 2008). Studies of multi-center LQT1 registries with hundreds 
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of patients suggest that the risk for LQT1 related cardiac events is related to the 
type/location of the LQT1 mutation (Zereba et al., 2003; Moss et al., 2007; Goldenberg et al.,  
 
 
Fig. 4. A cartoon for two possible mechanisms of Kv ǂ-subunit co-assembly. The images 
show Kv tetramers from the “extracellular” view. The first scenario assumes that WT (blue) 
and mutant (red) Kv ǂ-subunits (blue) co-assemble both equally and randomly so only 
1/16th of the total number of channels is all WT or mutant. The other 14/16ths of the channels 
are a combination of WT and mutant Kv ǂ-subunits with varying stoichometries. If the WT 
and mutant Kv ǂ-subunits do not co-assemble, then half of the channels are all WT or 
mutant (January et al., 2000). The structural model for the Kv7.1 ǂ-subunits used to generate 
the channels shown was developed by Smith and colleagues (2007). 
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2008; Jons et al., 2009). About 80% of LQT1 mutations are missense, and genetic testing for 
LQT1 is commercially available, but the diagnostic and prognostic value of a genotype 
positive test is limited because it does not distinguish between relatively benign or 
pathogenic variants (Kapa et al., 2009). Current treatments for LQT1 include life-style 
modification, ǃ-blockers, implantable cardioverter defibrillators (ICDs), and/or left 
cardiac sympathetic denervation (Ruan et al., 2008). A major challenge for clinicians is to 
determine which therapeutic strategies are most appropriate for an individual. While 
many considerations need to be made, in vitro patch clamp studies of individual LQT1 
mutations will provide a wealth of information, including identifying dominant negative 
functional phenotypes that may predict a more severe LQT1 clinical phenotype (Moss et 
al., 2007). 
The most common way to determine if LQT1 mutations cause dominant negative 
suppression is to co-express WT and mutant channels in the heterologous expression 
systems. Initially a common heterologous expression system was Xenopus laevis oocytes. 
Indeed, the first studies that measured the functionality of LQT1-linked mutation utilized 
this system with the two-electrode voltage-clamp (Wang et al., 1999; Shalaby et al., 1997). 
An advantage to the Xenopus system is that investigators can control the amount of WT 
and mutant cRNA injected into cell. Unfortunately Xenopus oocytes express a Kv7 isoform 
that can make experiments with exogenously added Kv7.1/KCNE1 difficult to interpret 
(Lesage et al., 1993). Additionally, Xenopus oocytes are cultured at room temperature and 
the trafficking of many different LQT-linked mutations are temperature sensitive, which 
can also complicate the interpretation of the data (Zhou et al., 1999; Ficker et al., 2000; 
Anderson et al., 2006).  
The whole-cell patch clamp technique of transiently expressing mammalian is an effective 
way to determine whether LQT1 mutations cause dominant negative effects. Mammalian 
cells can be transfected using chemical or electroporation techniques with Kv7.1 cDNA in 
plasmid expression vectors that contain WT-Kv7.1 or mutant Kv7.1 constructs. A 
disadvantage to this technique is that the uptake of the plasmid DNA is uncontrolled. 
Scenarios that further complicate this is that the cDNA for KCNE1 auxiliary channel 
subunits is also needed for transfection in order to generate native-like IKs (Barhanin et al., 
1996; Sanguinetti et al., 1996). For co-expression studies that utilize multiple plasmids, 
WT-Kv7.1 and mutant cDNA plasmids are typically transfected in a 50:50 ratio (to mimic 
heterozygousity) using the total equivalent cDNA plasmid concentrations as in parallel 
experiments with WT or mutant only transfections. To favor the selection of cells that 
express multiple cDNA plasmids, cells are typically co-transfected with a fluorescent 
protein cDNA expression plasmid (i.e. green fluorescent proteins or GFP). The 
assumption is that cells expressing the fluorescent protein are likely to express the other 
plasmids as well. 
Bartos and colleagues recently determined the effect of co-expressing WT-Kv7.1 and the 
LQT1-linked missense mutations E160K-Kv7.1 in Human Embryonic Kidney 293 (HEK293) 
(Bartos et al., 2011). This mutation has been previously characterized (Silva & Rudy, 2009; 
Wu D et al., 2010; Silva & Rudy, 2010;). The appropriate nucleotide change to generate the 
E160K-Kv7.1 mutations was engineered in the WT Kv7.1 (WT-Kv7.1) cDNA subcloned in 
pcDNA3 mammalian expression vector using the QuickChange Site Directed Mutagenesis 
www.intechopen.com
 Patch Clamp Technique 
 
242 
Kit (Stratagene, La Jolla, CA). HEK293 cells were transfected using Superfect (Qiagen 
Valencia, CA). Cells transfected with WT-Kv7.1 (3 μg) plasmid DNA expressed small 
currents that did not resemble IKs, and so to recapitulate IKs-like currents, cells were also 
transfected with KCNE1 (3 μg) plasmid DNA (total concentration was 6 μg). The final ratio 
of KCNE1 to Kv7.1 cDNA ratio is ~2:1. For co-expression studies (to mimic heterozygousity), 
they transfected KCNE1 (3 μg), WT-Kv7.1 (1.5 μg), and E160K-Kv7.1 (1.5 μg) plasmid DNA. 
Additionally, They transfected a third set of cells with KCNE1 (3 μg) and E160K-Kv7.1 (3 
μg). Cells were also transfected with enhanced GFP cDNA subcloned in pKR5 expression 
plasmid (0.3 μg). The cells were cultured in Minimum Essential Media (with 10% Fetal 
Bovine Serum) at 37 oC in 5% CO2 and analyzed 24-30 hrs after transfection. Functional 
analyses were done using standard whole cell patch clamp technique on GFP positive cells. 
An Axopatch-200B patch clamp amplifier (Axon Instruments, Union City, CA) was used to 
measure macroscopic currents and cell capacitance. The uncompensated pipette resistances 
were 1-2 MΩ and series resistance was compensated between up to 95%. pCLAMP 10 
software (Axon Instruments, Union City, CA) was used to acquire current signals and 
Origin (7.0, Microcal, Northhampton, MA) was used for performing data analyses. The 
external solution contained (in mM) 137 NaCl, 4 KCl, 1.8 CaCl2, 1 MgCl2, 10 glucose, and 10 
HEPES (pH 7.4 with NaOH), and an internal pipette solution contained (in mM) 130 KCl, 1 
MgCl2, 5 EDTA, 5 MgATP, 10 HEPES (pH 7.2 with KOH). Figure 5 shows representative 
families of whole-cell currents measured from cells expressing KCNE1 with WT-Kv7.1, WT- 
and E160K-Kv7.1, E160K-Kv7.1. The currents were measured by applying “step” pulses 
from -80 mV to 70 mV in 10 mV increments for 5 s, followed by a “tail” pulse to -50 mV for 5 
s. The intersweep holding potential and duration was -80 mV and 10 s, respectively. Cells 
expressing WT-Kv7.1 exhibited large macroscopic currents that resembled native IKs. Cells 
expressing WT- and E160K-Kv7.1 showed currents with similar characteristics as IKs, but the 
amplitudes were smaller than cells expressing WT-Kv7.1. Similar to that previously 
reported, cells expressing E160K-Kv7.1 did not generate hardly any current at all (Silva et al., 
2009; Wu et al., 2010; Silva et al., 2010; Bartos et al., 2010). The mean peak tail current  
 
 
Fig. 5. The LQT1-linked mutation E160K-Kv7.1 causes dominant negative suppression of 
WT-Kv7.1. Representative families of whole-cell currents recorded from HEK293 cells 
expressing KCNE1 and WT-Kv7.1 , WT- & E160K-Kv7.1, or E160K-Kv7.1. The 
corresponding voltage protocol used to measure the currents is also shown. Several 
mechanistic and computational studies suggest that E160K-Kv7.1 causes a loss of function 
by alter gating (Silva et al., 2009; Wu D et al., 2010; Silva et al., 2010; Bartos et al, 2011). 
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data for cells expressing WT-Kv7.1 or WT- and E160K-Kv7.1 were described using the 
Boltzmann function: 
 I = (IMIN-IMAX )/(1+e(V-V½)/k) + IMAX   (1) 
where IMIN is the minimally activated current; IMAX is the maximally activated current; V½ is 
the mid-point potential for half maximal activation; and k is the slope factor. Compared to 
cells expressing WT-Kv7.1, cells expressing WT- and E160K-Kv7.1 did not alter IMIN, V½, or 
k, but it did reduce IMAX by more than half that of cells expressing WT-Kv7.1. These data 
suggest that E160K-Kv7.1 causes dominant negative suppression of WT-Kv7.1. Additionally, 
this mutation is associated with a relatively severe LQT1-related clinical phenotype (Silvia et 
al., 2009). 
3.2 Long QT type 2 
Similar to LQT1, LQT2 is linked to hundred of different KCNH2 mutations (Kapa et al., 2009; 
http://www.fsm.it/cardmoc/); mutations in KCNH2 account for ~30-35% of congenital 
LQT cases (Yuan et al., 2008; Kapa et al., 2009); and heterologous expression studies suggest 
that many LQT2 mutations throughout the Kv11.1 ǂ-subunit cause a loss-of-function 
(Sanguinetti et al., 1996; Zhou et al., 1998; Zhou et al., 1999; Chen et al., 1999; Furutani et al., 
1999; Nakajima et al., 1999; Lees-Miller et al., 2000; Huang et al., 2001; Paulussen et al., 2002; 
Hayashi et al., 2002; Yang et al., 2002; Johnson et al., 2003; Hayashi et al., 2004; Rossenbacker  
 
Fig. 6. Trafficking-deficient LQT2-linked mutations generate a spectrum of functional 
phenotypes. Maximally activated currents were measured from cells expressing WT-Kv11.1, 
mutant Kv11.1, or WT and mutant Kv11.1 (Modified from Anderson et al., 2006). The 
relative amplitudes compared to WT-Kv11.1 are shown. Mutations expressed alone all 
reduced maximally activated current by > 0.5 (black). Co-expression of WT and Kv11.1 
mutations suggested that are caused dominant negative effects and reduced maximally 
activated current by >0.5 (red), whereas others resulted in haploinsufficiency and reduced 
maximally activated current by ~0.5 (blue). 
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et al., 2005; Anderson et al., 2006; Gong et al., 2007). Studies suggest that approximately 90% 
of LQT2 missense mutations cause a loss-of-function preventing the trafficking of the 
mutant Kv11.1 to the cell surface membrane (Anderson et al., 2006). These “trafficking-
deficient” mutations can cause dominant negative effects by inhibiting the trafficking of 
WT-Kv11.1 (Ficker et al., 2000). Using similar techniques as described above co-expressing 
WT-Kv7.1 and LQT1 mutations, Anderson and colleagues (2006) co-expressed WT-Kv11.1 
with different trafficking-deficient LQT2 mutations in HEK293 cells. Cells were depolarized 
to 50 mV for 5 seconds, and  the maximally activated peak tail IKv11.1 was measured at a test 
pulse to −120 mV for 3 seconds. Figure 6 shows the relative mean peak amplitude of tail 
current measured from cells expressing only the trafficking-deficient LQT2 mutations or co-
expressing WT-Kv11.1. The data suggest some trafficking-deficient LQT2 mutations can 
cause dominant negative effects whereas others cause haploinsufficiency.  
 
Fig. 7. A cartoon showing the different chaperones that regulate the trafficking of Kv11.1 in 
the secretory pathway. In the ER, several different chaperones and co-chaperones, including 
calnexin (clns), CHIP, heat shock proteins 40, 70 ,90 (hsp40, hscp70, hsp90), hop, and 
FKBP38 associate with Kv11.1. Misfolded Kv11.1 is prevented from trafficking into the 
secretory pathway in Endoplasmic Reticulum Exit Sites (ERES) and is degraded in the 
transolocan/proteasomal pathway. 
Trafficking-deficient LQT2 channels are retained in the Endoplasmic Reticulum (ER). 
Several studies suggest that the mutations cause “misofolding” of Kv11.1 and cellular 
quality control mechanisms prevent its export into the secretory pathway (Ficker 2003; 
Delisle et al., 2005, Gong et al, 2005; Gong et al., 2006; Walker et al., 2007; Walker et al., 2010; 
Li et al., 2010). Indeed, many different molecular chaperone proteins that regulate the 
trafficking of WT-Kv11.1 and LQT2 mutations have been identified (Figure 7). Misfolded 
Kv11.1 undergoes degradation through the proteasome pathway. To understand how  
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Fig. 8. A cartoon showing how some trafficking-deficient LQT2 mutations may disrupt 
distinct steps in Kv11.1 biogenesis. Trafficking-deficient LQT2 mutations may cause 
haploinsufficiency by preventing the oligomerization or co-assembly of WT- and mutant 
Kv11.1 ǂ-subunits. Alternatively, mutant Kv11.1 ǂ-subunits may cause dominant negative 
effects by co-assembling with WT-Kv11.1 and disrupt pore/voltage sensor formation or 
formation of proximity between the amino (NH2) or carboxy (COOH) termini. The cartoon 
shows the different stages of biogenesis, from the formation of secondary structures 
(cylinders) to the a folded channel (large cylinder with a circle).  
trafficking-deficient LQT2 mutations may cause dominant negative or haploinsufficiency, 
the steps that underlie the assembly and folding of Kv channel proteins during biogenesis 
need to be understood. Schulteis and colleagues (1998) proposed the following sequence 
of  events during Shaker K+ channel biogenesis in the ER: 1) membrane insertion and core-
glycosylation, 2) assembly of Shaker ǂ and ǃ subunit channel proteins, 3) formation of the 
pore and voltage sensor, and 4) formation of proximity between adjacent amino and 
carboxy termini. Assuming a similar sequence of events for Kv11.1 (Figure 8), then 
trafficking-deficient LQT2 mutations may be  capable of disrupting different steps in 
Kv11.1 channel biogenesis to cause either dominant negative or haploinsufficiency. LQT2 
mutations that do not co-assemble do not cause dominant negative suppression of WT-
Kv11.1 channel proteins (Ficker et al., 2002) and this would suggest that some trafficking-
deficient LQT2 mutations disrupt Kv11.1 biogenesis before the co-assembly step(s). 
Dominant negative trafficking-deficient LQT2 disrupt Kv11.1 biogenesis steps after co-
assembly. The latter group may disrupt Kv11.1 biogenesis steps such as the folding of the 
voltage sensor/pore, or the formation of proximity between adjacent amino and carboxy 
termini. 
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3.3 Summary 
The most common cardiac channelopathies are caused by mutations in KCNQ1 (Kv7.1) and 
KCNH2 (Kv11.1) that follow a dominant inheritance pattern and cause LQT1 and LQT2, 
respectively. The vast majority of these mutations are missense, and they can co-assemble 
with WT ǂ-subunits to cause effects that range from less than or more than (dominant 
negative) haploinsufficiency. In vitro techniques that utilize the whole cell patch clamp can 
identify dominant negative mutations that suppress channel function and/or trafficking. 
We conclude that the patch clamp technique is useful for identifying particularly pathogenic 
LQT1 and LQT2 mutations. 
4. Conclusions 
Cardiac channelopathies have informed us about the channels and proteins that are 
important for atrial and ventricular excitability. Correlations between in vitro and clinical 
data suggest that patch clamp technique can provide prognostic information about 
individual mutations. We expect advancements in genotyping and high throughput 
molecular, tissue culture, and patch clamp techniques may enable clinicians to assess the 
risk of individual patient mutations identified through genotyping using in vitro patch 
clamp assays. 
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